These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 29028121

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PD-1 inhibitor induced alopecia areata.
    Guidry J, Brown M, Medina T.
    Dermatol Online J; 2018 Dec 15; 24(12):. PubMed ID: 30677804
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
    Nardin C, Jeand'heur A, Bouiller K, Valnet-Rabier MB, Dresco F, Castagna J, Mareschal A, Carlet C, Nerich V, Limat S, Puzenat E, Aubin F.
    J Am Acad Dermatol; 2020 Mar 15; 82(3):770-772. PubMed ID: 31734192
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R, Metelitsa AI, Naert KA.
    Am J Dermatopathol; 2018 Jul 15; 40(7):523-526. PubMed ID: 29924748
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
    Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P.
    Melanoma Res; 2016 Aug 15; 26(4):413-6. PubMed ID: 27031539
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, Payne AS, Chu EY.
    J Cutan Pathol; 2016 Sep 15; 43(9):787-91. PubMed ID: 27161449
    [Abstract] [Full Text] [Related]

  • 16. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R, Aubin F, Roche-Kubler B, Puzenat E.
    Ann Dermatol Venereol; 2018 Feb 15; 145(2):116-119. PubMed ID: 29221649
    [Abstract] [Full Text] [Related]

  • 17. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.
    Eur J Cancer; 2016 Jun 15; 60():190-209. PubMed ID: 27085692
    [Abstract] [Full Text] [Related]

  • 18. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
    Fiset PO, Shapera S, Butler MO, Tsao MS.
    Ann Oncol; 2016 Aug 15; 27(8):1649-50. PubMed ID: 27091805
    [No Abstract] [Full Text] [Related]

  • 19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun 15; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 20. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
    Thomas M, Armenti ST, Ayres MB, Demirci H.
    JAMA Ophthalmol; 2018 May 01; 136(5):553-556. PubMed ID: 29677240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.